

1 **Title:**

2 Safety Monitoring of Mpox Vaccines in Adults Aged 18–64 Years during the 2022 Mpox Outbreak in the  
3 U.S.

4

5 **Authors:**

6 Joann F. Gruber, PhD, MSPH,<sup>a</sup> Kathryn Matuska, BA,<sup>b</sup> Carla E. Zelaya, PhD, MSc,<sup>a</sup> Jing Wang, BA,<sup>b</sup> Cheryl N  
7 McMahonill-Walraven, PhD, MSW,<sup>c</sup> Lauren Peetluk, PhD, MPH,<sup>d</sup> Alex Secora, PhD,<sup>e</sup> Shwetha Krishnakumar,  
8 BA,<sup>b</sup> Mao Hu, BS,<sup>b</sup> Kandace L. Amend, PhD, MPH,<sup>d</sup> Jennifer Song, MA, MURP,<sup>d</sup> Daniel C. Beachler, PhD,  
9 MHS,<sup>f</sup> Patricia C. Lloyd, PhD, ScM,<sup>a</sup> Yoganand Chillarige, MPA,<sup>b</sup> Jane A. Gwira, MD, MPH,<sup>a</sup> Wafa Tarazi,  
10 PhD, MHPA,<sup>g</sup> Tainya C. Clarke, PhD, MPH, MSc,<sup>a</sup> Djeneba Audrey Djibo, PhD,<sup>c</sup> Richard A. Forshee, PhD,<sup>a</sup>  
11 Azadeh Shoaibi, PhD, MHS,<sup>a</sup> Steven A. Anderson, PhD, MPP<sup>a</sup>

12

13 **Author Affiliations:**

14 <sup>a</sup> U.S. Food and Drug Administration, Silver Spring, MD, USA

15 <sup>b</sup> Acumen LLC, Burlingame, CA, USA

16 <sup>c</sup> CVS Health, Blue Bell, PA, USA

17 <sup>d</sup> Optum Epidemiology, Boston, MA, USA

18 <sup>e</sup> IQVIA, Falls Church, VA, USA

19 <sup>f</sup> Carelon Research, Wilmington, DE, USA

20 <sup>g</sup> OptumServe, Falls Church, VA, USA

21

22 **Author Email Addresses:**

23 Joann F. Gruber ([Joann.Gruber@fda.hhs.gov](mailto:Joann.Gruber@fda.hhs.gov)), Kathryn Matuska ([kmatuska@acumenllc.com](mailto:kmatuska@acumenllc.com)), Carla E.

24 Zelaya ([Carla.Zelaya@fda.hhs.gov](mailto:Carla.Zelaya@fda.hhs.gov)), Jing Wang ([jwang@acumenllc.com](mailto:jwang@acumenllc.com)), Cheryl N McMahonill-Walraven

25 (cherylwalraven@verizon.net), Lauren Peetluk ([lspeetluk@gmail.com](mailto:lspeetluk@gmail.com)), Alex Secora  
26 ([alex.secora@iqvia.com](mailto:alex.secora@iqvia.com)), Shwetha Krishnakumar ([skrishnakumar@acumenllc.com](mailto:skrishnakumar@acumenllc.com)), Mao Hu  
27 ([mhu@acumenllc.com](mailto:mhu@acumenllc.com)), Kandace L. Amend ([kandace.amend@optum.com](mailto:kandace.amend@optum.com)), Jennifer Song  
28 ([jennifer.song@optum.com](mailto:jennifer.song@optum.com)), Daniel C. Beachler ([daniel.beachler@carelon.com](mailto:daniel.beachler@carelon.com)), Patricia C. Lloyd  
29 ([Patricia.Lloyd@fda.hhs.gov](mailto:Patricia.Lloyd@fda.hhs.gov)), Yoganand Chillarige ([ychillarige@acumenllc.com](mailto:ychillarige@acumenllc.com)), Jane A. Gwira  
30 ([jane.gwira@fda.hhs.gov](mailto:jane.gwira@fda.hhs.gov)), Wafa Tarazi ([Wafa.Tarazi@Lewin.com](mailto:Wafa.Tarazi@Lewin.com)), Tainya C. Clarke  
31 ([Tainya.Clarke@fda.hhs.gov](mailto:Tainya.Clarke@fda.hhs.gov)), Djeneba Audrey Djibo ([audrey.djibo@cvshealth.com](mailto:audrey.djibo@cvshealth.com)), Richard A. Forshee  
32 ([Richard.Forshee@fda.hhs.gov](mailto:Richard.Forshee@fda.hhs.gov)), Azadeh Shoaibi ([azadeh.shoaibi@nih.gov](mailto:azadeh.shoaibi@nih.gov)), Steven A. Anderson  
33 ([Steven.Anderson@fda.hhs.gov](mailto:Steven.Anderson@fda.hhs.gov))

34

35 **Corresponding Author:**

36 Joann F. Gruber, PhD, MSPH

37 Epidemiologist

38 Office of Biostatistics and Pharmacovigilance

39 Center for Biologics Evaluation and Research

40 U.S. Food & Drug Administration

41 10903 New Hampshire Ave., Building 71

42 Silver Spring, MD 20993

43 Email: [Joann.Gruber@fda.hhs.gov](mailto:Joann.Gruber@fda.hhs.gov)

44

45 **Abstract word count:** 150/150

46 **Manuscript word count:** 1984/2000

47 **Tables and Figures:** 4/4

48 **References:** 19/20

49 **Abstract**

50 Two vaccines (JYNNEOS; ACAM2000) were available in the United States to prevent mpox during the  
51 2022 clade II mpox outbreak with the majority of people receiving JYNNEOS. As part of the Biologics  
52 Effectiveness and Safety (BEST) Initiative, FDA monitored the safety of JYNNEOS using three commercial  
53 health plan claims databases supplemented with local and state Immunization Information System data.  
54 We assessed vaccine uptake, described the vaccinated population, monitored rates of 11 potential  
55 adverse events (AEs) following vaccination, and compared the observed AE rates to expected  
56 background rates. There were 152,001 JYNNEOS doses administered. Of the 92,340 people receiving at  
57 least one JYNNEOS dose, most were males (93.1%), aged 25–44 years (63.3%), lived in urban areas  
58 (98.7%), and 64.2% received a second dose. AE rates following JYNNEOS doses were similar to expected  
59 background rates. Additional safety studies of larger vaccinated populations may be needed to evaluate  
60 rare AEs including myocarditis/pericarditis.

61

62 **Keywords:** mpox, monkeypox virus, JYNNEOS, claims data, real-world data

63 **1. Introduction**

64 In 2022, a global outbreak of clade II mpox spread to areas without historically reported cases [1]. In  
65 the United States (U.S.), the first case was reported in May 2022. As of January 2024, there have been  
66 over 32,000 reported cases and 58 deaths in the U.S. [2]. While most of the cases occurred during the  
67 summer and fall of 2022, clade II mpox cases continue to be reported at low levels in the U.S. and other  
68 countries [3, 4].

69 Two orthopoxvirus vaccines (JYNNEOS and ACAM2000) were made available for the prevention  
70 of mpox in the U.S. during the 2022 outbreak. At the start of the outbreak, the Centers for Disease  
71 Control and Prevention (CDC) recommended vaccination for those with known or presumed exposure to  
72 mpox [5]; by the end of September 2022, CDC expanded recommendations to pre-exposure vaccination  
73 for those at highest risk [6]. The JYNNEOS vaccine is a two-dose vaccine (4 weeks apart) containing the  
74 Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) strain—a live, attenuated, non-replicating  
75 orthopoxvirus [7]—and considered safer for use in immunocompromised persons than other live  
76 vaccines [6]. It was licensed by the U.S. Food and Drug Administration (FDA) in 2019 for the prevention  
77 of mpox and smallpox in adults aged 18 years and older. The ACAM2000 vaccine contains a live,  
78 attenuated, replicating strain of the vaccinia virus and was initially licensed by FDA in 2007 for the  
79 prevention of smallpox only [8]. It was made available for use to prevent mpox under the Expanded  
80 Access Investigational New Drug mechanism [9]. However, ACAM2000 was not recommended for use in  
81 all populations during the 2022 clade II outbreak and was available only by special request [5].

82 There have been limited active and passive safety surveillance studies of the JYNNEOS vaccine  
83 published globally [10-12]. Large cohort-based safety studies assessing several potential adverse events  
84 (AEs) of interest have not been published to date.

85 As part of the Biologics Effectiveness and Safety (BEST) Initiative, FDA assessed the safety of  
86 JYNNEOS vaccines used during the 2022 clade II mpox outbreak by estimating the incidence rates of 11

87 potential adverse events (AEs) following JYNNEOS vaccination among U.S. adults aged 18–64 years using  
88 large U.S. based commercial health insurance claims databases supplemented with vaccination data  
89 from Immunization Information Systems (IIS) and compared these rates to the age-sex standardized  
90 expected rates for the vaccinated population.

## 91 **2. Methods**

92 Data from three U.S. commercial claims databases in the FDA BEST Initiative were used: Carelon  
93 Research (Elevance Health, including Anthem, and affiliated health plans), CVS Health (Aetna and  
94 affiliated health plans), and Optum (commercial health plans). To increase the capture of vaccines for  
95 people enrolled in these commercial insurance plans, claims data were supplemented with available  
96 local and state IIS data. The number of state IIS jurisdictions varied by database (CVS Health: 23, Carelon  
97 Research: 10, Optum: 6; Supplementary Table 1). Data were refreshed monthly to conduct near-real  
98 time surveillance as vaccines were administered. Our study population included individuals who  
99 received at least one dose of JYNNEOS and were aged 18–64 years at the time of vaccination. The study  
100 period started on May 10, 2022 and ended on July 4, 2023 (Carelon Research), June 30, 2023 (CVS  
101 Health), and July 8, 2023 (Optum). Exposure was defined as receipt of any dose of JYNNEOS, as  
102 identified by product codes such as Current Procedural Terminology/Healthcare Common Procedure  
103 Coding System codes, National Drug Codes, and CVX codes in any care setting in claims or IIS data [13].  
104 Since there was extremely limited use of ACAM2000 (N = 239 doses across the three databases), our  
105 monitoring focused on JYNNEOS only.

106 We assessed the count and trend of JYNNEOS doses over time. In addition, we summarized the  
107 distribution of demographic and geographic characteristics of the JYNNEOS vaccinated population and  
108 the percentage of people receiving a complete JYNNEOS vaccine series (i.e., at least two doses).

109 We monitored the occurrence of 11 potential AEs in outcome-specific risk windows following  
110 JYNNEOS vaccination. Potential AEs included serious AEs following other vaccinations including those

111 known or possibly related to smallpox vaccination. To be included in an AE-specific analysis, persons  
112 were required to be continuously enrolled in the health plan from the start of the AE-specific clean  
113 window through the date of vaccination, and must not have had the specific AE during the clean  
114 window. The list of AEs, pre-vaccination clean windows, and post-vaccination risk windows are detailed  
115 in Table 1. Claims-based AE algorithms were developed based on literature review and in consultation  
116 with clinical experts [13]. Observed rates per 100,000 person years of each AE following any JYNNEOS  
117 dose and corresponding exact 95% confidence intervals (CIs) were calculated [14]. Follow-up time  
118 continued from the start of the AE-specific risk window until a person experienced an AE, death,  
119 disenrollment, a third JYNNEOS or second ACAM2000 dose, or the end of the risk window. We  
120 aggregated all statistics across the three databases to protect privacy. To contextualize the observed  
121 rates, we estimated the age-sex standardized expected rates of each AE and 95% CIs [15] by applying  
122 approximate age-sex specific 2019 background rates (where available) (Supplementary Table 2),  
123 estimated using methods from prior work [16], to the age-sex distribution of the JYNNEOS-vaccinated  
124 population.

125         To investigate potential pre-existing comorbidities that could influence the risk of  
126 myocarditis/pericarditis following vaccination, we completed a review of all claims in the 365 days prior  
127 and 105 days following the myocarditis/pericarditis diagnosis that occurred 1–42 days following  
128 JYNNEOS vaccination. For those with available data, a clinician reviewed all claims to determine if  
129 persons had any pre-existing conditions for myocarditis/pericarditis.

130         This surveillance activity was conducted as part of the FDA public health surveillance mandate  
131 [17].

### 132 **3. Results**

133         A total of 152,001 JYNNEOS doses were observed with the majority administered between July  
134 and October of 2022 (Figure 1). Of the 92,340 people vaccinated with at least one JYNNEOS dose, most

135 were male (93.1%), 25–44 years of age at the time of first dose (63.3%), lived in urban areas (98.7%) and  
136 resided in Health and Human Services regions two (32.4%) and nine (32.5%) (Table 2). Among those who  
137 received a first dose of JYNNEOS, 64.2% received a second dose, but this differed by sex and age group  
138 (Supplementary Table 3).

139 There were 15 or fewer cases of each AE, and AE rates ranged from zero to 188.2 events per  
140 100,000 person-years (Figure 2). Historical background rates from 2019 were available for 9 of the 11  
141 AEs; background rates were not available for cardiomyopathy or the composite outcome of encephalitis,  
142 myelitis, or encephalomyelitis. There was overlap between the 95% CIs of observed and age-sex  
143 standardized expected rates. Point estimates of age-sex standardized expected background rates were  
144 higher than observed rates in all instances except two (myocarditis/pericarditis and anaphylaxis).  
145 However, observed rates of both outcomes were imprecise and based on 10 or fewer cases. For  
146 myocarditis/pericarditis, the rate in the 1–42 days following vaccination (N = 10 cases) was 90.2 (95% CI:  
147 43.3, 165.9) per 100,000 person-years compared to the age-sex standardized expected rate of 39.7 (95%  
148 CI: 25.7, 50.6) per 100,000 person-years. Of the ten persons with myocarditis/pericarditis in the 1–42  
149 days following a JYNNEOS dose, claims profile information was available for eight. Of the eight people,  
150 one had myocarditis and seven had pericarditis. Based on the claims profile review, the clinician  
151 determined that all eight people had at least one risk factor for myocarditis/pericarditis present prior to  
152 vaccination, including recent coronary artery bypass grafting, alcohol abuse, atrial fibrillation, HIV, or  
153 cardiomyopathy. For anaphylaxis, the rate was elevated, but extremely imprecise, due to very small case  
154 counts.

#### 155 **4. Discussion**

156 This active safety surveillance study was a large post-marketing study of JYNNEOS-vaccinated  
157 persons. Using U.S. commercial claims databases supplemented with IIS data, we monitored 11 AEs  
158 following approximately 150,000 JYNNEOS doses administered to persons aged 18–64 years. We found

159 relatively low counts and rates of AEs following JYNNEOS vaccinations. Rates were similar to age-sex  
160 standardized expected background rates for the nine outcomes with prior data available.

161 Myocarditis and pericarditis have been associated with receipt of replicating smallpox vaccines  
162 including Dryvax (10.4 events per 1,000 vaccinations) and ACAM2000 (5.7 events per 1,000 vaccinations)  
163 [8]. JYNNEOS is a non-replicating vaccine not known to be associated with myocarditis/pericarditis.

164 However, JYNNEOS vaccines were not used widely prior to the 2022 clade II mpox outbreak, so safety  
165 data are limited. In our study, there were very few claims-based cases of myocarditis/pericarditis  
166 observed following JYNNEOS-vaccination (i.e., 6 cases 1–21 days and 4 cases 22–42 days following  
167 vaccination). The Vaccine Safety Datalink, a CDC active surveillance system, reported 43,253 JYNNEOS  
168 doses during the 2022 clade II mpox outbreak and reported one case of myocarditis among vaccinated  
169 males in the 30 days following each dose of the vaccine (rate per million doses (95% CI): 39 (0.1, 217.1)  
170 and 67 (1.7, 374.4) for doses 1 and 2, respectively) [12]. A retrospective review of 3,235 JYNNEOS doses  
171 administered to 2,126 individuals aged 12 years and older who received at least one JYNNEOS dose  
172 reported 10 cardiac AEs (rate of 3.1 per 1,000 doses (95% CI: 1.5, 5.7)) in the 21 days following dose  
173 receipt, but no cases of myocarditis or pericarditis [18]. Our observed rates of myocarditis/pericarditis  
174 were based off a limited number of cases and were very imprecise, making it difficult to compare them  
175 to the age-sex standardized expected background rate. The data available indicate any differences may  
176 be a result of random variability. However, since myocarditis/pericarditis rates could possibly be  
177 elevated, we reviewed additional claims data for all persons with myocarditis/pericarditis (8 of 10  
178 available) to see if persons had other clinical factors (see “Results”) that could be associated with  
179 myocarditis/pericarditis. We found all persons had at least one pre-existing risk factor for  
180 myocarditis/pericarditis prior to vaccination. Based on these data, there is insufficient information to  
181 conclude there is increased risk of myocarditis/pericarditis following JYNNEOS vaccination.



182           Our study had several strengths. To our knowledge, this study was the largest post-marketing  
183 safety study of the JYNNEOS vaccine. The study population included adults enrolled in commercial  
184 insurance captured in large claims databases that collectively cover every U.S. state. During the study  
185 period, vaccines were only available through the Strategic National Stockpile, and largely administered  
186 through community-based vaccination initiatives, so they often did not generate a health insurance  
187 claim. Supplementing our claims data with data from several IIS was critical and made it possible to  
188 conduct this safety study.

189           Our study also had some limitations. Our age-sex standardized expected rates of AEs were  
190 based on age-sex specific background rates from the age-sex groupings from the general commercially  
191 insured population from 2019. These rates provided a general estimate for comparison; however, they  
192 may not represent the true expected background AE rates for the vaccinated population. Before  
193 September 2022, vaccines were recommended by CDC for populations at the highest risk of mpox [6].  
194 This population may have experienced different background rates of AEs because of higher levels of  
195 comorbidities, including HIV [19]. In addition, the time period and age categories used to estimate age-  
196 sex standardized expected background rates differed slightly from the present study. These differences  
197 could also influence the accuracy of the age-sex standardized expected rates. There were no available  
198 2019 background rates for cardiomyopathy or the composite outcome of encephalitis, myelitis, or  
199 encephalomyelitis, so we were unable to compare the observed rates to background rates. Finally,  
200 outcomes were identified using claims-based algorithms and were not chart-confirmed.

201           As part of the FDA BEST Initiative, this study used real-world data, including claims supplemented  
202 with IIS data, to monitor the uptake and safety of vaccines used to prevent mpox among U.S. adults  
203 aged 18–64 years during the 2022 clade II mpox outbreak. No significant safety concerns were identified  
204 following the receipt of JYNNEOS vaccines. Additional safety studies of larger vaccinated populations  
205 may be needed in the future to evaluate the potential for rare AEs including myocarditis/pericarditis.

## Tables and Figures

Table 1. List of clean windows and risk windows used for safety monitoring of JYNNEOS vaccination, by adverse event and healthcare setting, in U.S. adults aged 18–64 years.

<b>Adverse Event</b>	<b>Healthcare Setting<sup>a</sup></b>	<b>Clean Window (days)<sup>b</sup></b>	<b>Risk Window (days)</b>
Acute Myocardial Infarction	IP	365	1–28
Anaphylaxis	IP, OP-ED	30	0–1
Bell’s Palsy	IP, OP/PB	183	1-42
Cardiomyopathy	IP, OP-ED	365	1–42
Deep Vein Thrombosis	IP, OP/PB	365	1–28
Encephalitis, Myelitis, or Encephalomyelitis	IP	183	1–42
Guillain-Barré Syndrome	IP-primary position only	365	1–42
Myocarditis/Pericarditis	IP, OP-ED	365	1–21 & 1–42
Non-hemorrhagic Stroke	IP	365	1–28
Pulmonary Embolism	IP	365	1–28
Transverse Myelitis	IP, OP-ED	365	1–42

<sup>a</sup>Care setting definitions: IP refers to inpatient facility claims. IP-primary position only refers to only those inpatient claims which are the primary record on the claim. OP-ED refers to a subset of outpatient facility claims occurring in the emergency department. OP/PB refers to all outpatient facility claims, and professional/provider claims except those with a laboratory place of service.

<sup>b</sup>In order to be considered an incident occurrence of an AE, it must not be observed in a pre-specified period prior to vaccination.

Table 2. Demographic and geographic characteristics of U.S. adults aged 18–64 years who received at least one JYNNEOS dose.

<b>Characteristic</b>	<b>N</b>	<b>%</b>
<b>Total</b>	92,340	100
<b>Sex</b>		
Female	6,243	6.8
Male	85,947	93.1
Missing/Unknown	150	0.2
<b>Age (years)</b>		
18–24	6,635	7.2
25–34	33,269	36.0
35–44	25,202	27.3
45–54	15,344	16.6
55–64	11,890	12.9
<b>HHS Region</b>		
Region 1: CT, ME, NH, RI, VT	2,810	3.0
Region 2: NJ, NY, PR, VI	29,923	32.4
Region 3: DE, DC, MD, PA, VA, WV	3,532	3.8
Region 4: AL, FL, GA, KY, MS, NC, SC, TN	9,780	10.6
Region 5: IL, IN, MI, MN, OH, WI	6,474	7.0
Region 6: AR, LA, NM, OK, TX	4,708	5.1
Region 7: IA, KS, MO, NE	356	0.4
Region 8: CO, MT, ND, SD, UT, WY	2,075	2.2
Region 9: AZ, CA, HI, NV, AS, MP, FM, GU, MH, PW	30,045	32.5
Region 10: AK, ID, OR, WA	2,598	2.8
Missing/Unknown	39	0.0
<b>Urban/Rural</b>		
Urban	91,097	98.7
Rural	1,180	1.3
Missing/Unknown	63	0.1

Figure 1. Monthly counts of JYNNEOS doses administered to U.S. adults aged 18–64 years from May 2022 through July 2023.





Figure 2. Observed and age-sex standardized expected background rates of adverse events following JYNNEOS doses administered to U.S. adults aged 18–64 years.



\* Cells with < 5 Outcomes Suppressed

## **Funding**

This work was supported by the U.S. Food and Drug Administration, whom were an integral part of the study design, implementation and interpretation of the analysis, writing of the report, and the decision to submit the manuscript for publication.

## **Declaration of Competing Interest**

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Daniel C. Beachler reports financial support was provided by Elevance Health Inc. Daniel C. Beachler reports a relationship with Elevance Health Inc that includes: employment and equity or stocks. Djeneba Audrey Djibo and Cheryl N McMahill-Walraven are employees of CVS Health and may own stock as part of employment. Jennifer Song and Kandace Amend report financial support was provided by OptumInsight Inc. Jennifer Song and Kandace Amend report a relationship with OptumInsight Inc that includes: employment and equity or stocks. Lauren Peetluk reports financial support was provided by Optum. Lauren Peetluk reports a relationship with Optum that includes: equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## **Acknowledgments**

We would like to thank Cheuk Yi Lau (Acumen), Natalie Sisto (Acumen), Wenya Grace Yang (Optum Serve Consulting), Alexandra Stone (Optum Serve Consulting), Emily Myers (Optum Serve Consulting), Nwanneamaka Ume (Optum Serve Consulting), Megan Ketchell (Optum Serve Consulting), Kathryn Federici (Optum Serve Consulting), Vaibhav Sharma (CVS Health), Smita Bhatia (CVS Health), Carla Brannan (CVS Health), Ana Martinez-Baquero (CVS Health), Aparna Srikanti (CVS Health), Nancy Shaik (CVS Health), Ruth Weed (IQVIA), Rosenie Thelus (IQVIA), Nerissa Williams (IQVIA), Michael Goodman

(IQVIA), Shiva Vojjala (Carelon Research), Ramya Avula (Carelon Research), Shiva Chaudhary (Carelon Research), Shanthi P Sagare (Carelon Research), Ramin Riahi (Carelon Research), Lauren Parlett (Carelon Research), Grace Stockbower (Carelon Research), Douglas Rouse (FDA), Henry Zhang (FDA), and Krista Fekecs (FDA).

## References

1. World Health Organization (WHO). *Disease Outbreak News Multi-country monkeypox outbreak: situation update*. 2022 [accessed October 1, 2024]; Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON393>.
2. Centers for Disease Control and Prevention (CDC). *Archive Home: Ongoing 2022 Global Outbreak Cases and Data*. [accessed October 1, 2024]; Available from: [https://archive.cdc.gov/#/details?archive\\_url=https://archive.cdc.gov/www\\_cdc\\_gov/poxvirus/mpox/response/2022/index.html](https://archive.cdc.gov/#/details?archive_url=https://archive.cdc.gov/www_cdc_gov/poxvirus/mpox/response/2022/index.html).
3. Centers for Disease Control and Prevention (CDC). *Ongoing Clade II Mpox Global Outbreak*. [accessed October 1, 2024]; Available from: <https://www.cdc.gov/mpox/outbreaks/2022/index-1.html>.
4. Tuttle, A., et al., *Notes from the Field: Clade II Mpox Surveillance Update - United States, October 2023-April 2024*. MMWR Morb Mortal Wkly Rep, 2024. **73**(20): p. 474-476.
5. Centers for Disease Control and Prevention (CDC). *CDC, Poxvirus, Monkeypox, Health Departments: Vaccine Considerations*. 2022 [accessed October 1, 2024]; Available from: <https://web.archive.org/web/20220811084742/https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/overview.html>.
6. Centers for Disease Control and Prevention (CDC). *Interim Clinical Considerations for Use of Vaccine for Mpox Prevention in the United States*. 2024 [accessed October 1, 2024]; Available from: [https://www.cdc.gov/mpox/hcp/vaccine-considerations/vaccination-overview.html?CDC\\_AAref\\_Val=https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html](https://www.cdc.gov/mpox/hcp/vaccine-considerations/vaccination-overview.html?CDC_AAref_Val=https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html).
7. Food and Drug Administration (FDA). *Full Prescribing Information - JYNNEOS*. 2023 [accessed October 1, 2024]; Available from: <https://www.fda.gov/media/131078/download>.



8. Food and Drug Administration (FDA). *Full Prescribing Information - ACAM200*. 2024 [accessed November 8, 2024]; Available from: <https://www.fda.gov/media/75792/download?attachment>.
9. U.S. Food and Drug Administration (FDA). *Key Facts About Vaccines to Prevent Monkeypox Disease*. 2022 [accessed October 1, 2024]; Available from: <https://www.fda.gov/vaccines-blood-biologics/vaccines/key-facts-about-vaccines-prevent-monkeypox-disease>.
10. Liu, H., et al., *Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity*. *Emerg Microbes Infect*, 2024. **13**(1): p. 2387442.
11. Duffy, J., et al., *JYNNEOS Vaccine Safety Surveillance During the 2022 Mpox Outbreak Using the Vaccine Adverse Event Reporting System and V-safe, United States, 2022 to 2023*. *Sex Transm Dis*, 2024. **51**(8): p. 509-515.
12. Duffy, J., et al., *Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022*. *MMWR Morb Mortal Wkly Rep*, 2022. **71**(49): p. 1555-1559.
13. Food and Drug Administration (FDA). *Safety Surveillance of Vaccines Used for Mpox Prevention: Active Monitoring Master Protocol: Code List*. 2022 [accessed October 1, 2024]; Available from: <https://bestinitiative.org/wp-content/uploads/2023/01/Mpox-Vax-Safety-Monitoring-Protocol-Code-List-2022.xlsx>.
14. Ulm, K., *A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)*. *Am J Epidemiol*, 1990. **131**(2): p. 373-5.
15. Parker, J.D., et al., *National Center for Health Statistics data presentation standards for rates and counts*. *Vital Health Stat*, 2023. **2**(200).
16. Food and Drug Administration (FDA). *Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring*. 2022 [accessed October 8, 2024]; Available from:

[https://bestinitiative.org/wp-content/uploads/2022/08/Background-Rates-of-Adverse-Events-of-Special-Interest\\_for\\_COVID-19\\_Vaccine\\_Safety\\_Monitoring-All\\_Files.zip](https://bestinitiative.org/wp-content/uploads/2022/08/Background-Rates-of-Adverse-Events-of-Special-Interest_for_COVID-19_Vaccine_Safety_Monitoring-All_Files.zip).

17. Office for Human Research Protections US Department of Health and Human Services. *45 CFR §46* 2010 [accessed November 8, 2024]; Available from: <https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html>.
18. Sharff, K.A., et al., *Cardiac events following JYNNEOS vaccination for prevention of Mpox*. Vaccine, 2023. **41**(22): p. 3410-3412.
19. Delaney, K.P., et al., *Strategies Adopted by Gay, Bisexual, and Other Men Who Have Sex with Men to Prevent Monkeypox virus Transmission - United States, August 2022*. MMWR Morb Mortal Wkly Rep, 2022. **71**(35): p. 1126-30.

*Supplementary Data for Safety Monitoring of Mpox Vaccines in Adults Aged 18–64 Years during the 2022 Mpox Outbreak in the U.S.*

Supplementary Table 1. List of state Immunization Information System jurisdictions that were used to supplement JYNNEOS vaccination data in at least one of the commercial claims databases.

---

State IIS Jurisdictions

---

Arizona  
California<sup>a</sup>  
Colorado  
Delaware  
Georgia  
Illinois<sup>a</sup>  
Indiana  
Kentucky  
Maryland  
Massachusetts  
Michigan  
Minnesota  
Nevada  
New Jersey  
New Mexico  
New York<sup>a</sup>  
North Carolina  
Oklahoma  
Pennsylvania<sup>a</sup>  
Texas  
Vermont  
Virginia  
Washington  
Wisconsin

---

<sup>a</sup> May or may not include local IIS jurisdictions within that state.

Supplementary Table 2. Sex- and age- specific 2019 background rates for each adverse event<sup>a</sup> estimated from prior surveillance work using aggregated data from CVS Health, Carelon Research, and Optum commercial claims databases.

Adverse Event	Sex	Age (years)	Rate per 100,000 Person-Years	
Acute Myocardial Infarction	Males	18–25	6.2	
	Males	26–35	17.5	
	Males	36–45	84.5	
	Males	46–55	244.3	
	Males	56–64	446.4	
	Females	18–25	2.6	
	Females	26–35	7.8	
	Females	36–45	33.3	
	Females	46–55	89.9	
	Females	56–64	180.3	
	Males	18–25	13.9	
	Males	26–35	10.4	
	Males	36–45	11.6	
	Males	46–55	11.9	
Anaphylaxis	Males	56–64	12.1	
	Females	18–25	22.0	
	Females	26–35	14.5	
	Females	36–45	15.9	
	Females	46–55	15.4	
	Females	56–64	11.8	
	Bell's Palsy	Males	18–25	36.3
		Males	26–35	65.7
Males		36–45	94.0	
Males		46–55	128.3	
Males		56–64	151.3	
Females		18–25	47.7	
Females		26–35	85.4	
Females		36–45	112.8	
Females		46–55	138.9	
Females		56–64	150.5	
Deep Vein Thrombosis		Males	18–25	35.7
	Males	26–35	75.2	
	Males	36–45	162.8	

	Males	46–55	337.7
	Males	56–64	582.2
	Females	18–25	53.9
	Females	26–35	116.3
	Females	36–45	200.7
	Females	46–55	291.3
	Females	56–64	392.4
Guillain-Barré Syndrome	Males	18–25	1.8
	Males	26–35	1.8
	Males	36–45	2.5
	Males	46–55	3.3
	Males	56–64	3.9
	Females	18–25	1.2
	Females	26–35	2.0
	Females	36–45	2.1
	Females	46–55	2.3
	Females	56–64	2.2
Myocarditis/Pericarditis	Males	18–25	38.2
	Males	26–35	36.6
	Males	36–45	38.3
	Males	46–55	44.0
	Males	56–64	56.0
	Females	18–25	16.8
	Females	26–35	17.4
	Females	36–45	25.1
	Females	46–55	31.7
	Females	56–64	39.0
Non-Hemorrhagic Stroke	Males	18–25	4.2
	Males	26–35	10.1
	Males	36–45	33.9
	Males	46–55	93.4
	Males	56–64	202.7
	Females	18–25	5.1
	Females	26–35	11.8
	Females	36–45	28.6
	Females	46–55	60.7
	Females	56–64	123.8
Pulmonary Embolism	Males	18–25	20.2
	Males	26–35	43.8
	Males	36–45	91.6
	Males	46–55	191.3

Transverse Myelitis	Males	56–64	327.6
	Females	18–25	45.0
	Females	26–35	81.6
	Females	36–45	131.3
	Females	46–55	178.1
	Females	56–64	238.4
	Males	18–25	0.6
	Males	26–35	0.8
	Males	36–45	1.0
	Males	46–55	1.8
	Males	56–64	1.9
	Females	18–25	1.1
	Females	26–35	1.7
	Females	36–45	1.7
	Females	46–55	1.7
	Females	56–64	1.8

<sup>a</sup> Background rates for cardiomyopathy or encephalitis, myelitis, or encephalomyelitis were not estimated in 2019 and therefore, were not available to use in this study.

Supplementary Table 3. Number and percentage of people receiving a complete JYNNEOS vaccine series among U.S. adults aged 18–64 years who received at least one JYNNEOS dose.

Characteristic	Receiving	Receiving	
	≥ 1 Dose	≥ 2 Doses	
	N	N	%
<b>Total</b>	92,340	59,277	64.2
<b>Sex</b>			
Female	6,243	2,869	46.0
Male	85,947	56,335	65.5
Missing/Unknown	150	73	48.7
<b>Age (years)</b>			
18–24	6,635	3,091	46.6
25–34	33,269	19,663	59.1
35–44	25,202	16,869	66.9
45–54	15,344	10,947	71.3
55–64	11,890	8,707	73.2